The p38α mitogen-activated protein kinase as a central nervous system drug discovery target

BMC Neuroscience

Volumn 9, Issue SUPPL. 2, 2008, Pages

  Borders, Aaron S ^a   de Almeida, Lucia ^a   Van Eldik, Linda J ^a   Watterson, D Martin ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; CYTOKINE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 14 INHIBITOR DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; SB 681323; SCIO 469; UNCLASSIFIED DRUG; VX 702; ENZYME INHIBITOR;

BRAIN INJURY; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG PENETRATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; INFLAMMATORY DISEASE; NERVE DEGENERATION; NONHUMAN; REGULATORY MECHANISM; RISK FACTOR; ANIMAL; CENTRAL NERVOUS SYSTEM; CHEMICAL STRUCTURE; CHEMISTRY; DEGENERATIVE DISEASE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CENTRAL NERVOUS SYSTEM; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 14; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 57449093329     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-9-S2-S12     Document Type: Conference Paper

References (68)

1. Van Eldik LJ Thompson WL Ralay Ranaivo H Behanna HA Watterson DM Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: Function-based and target based discovery approaches Int Rev Neurobiol 2007, 82:277-296. 17678967
2. Kyriakis JM Avruch J Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation Physiol Rev 2001, 81:808-869.
3. O'Neill LA Targeting signal transduction as a strategy to treat inflammatory diseases Nat Rev Drug Discov 2006, 5:549-563. 16773072
4. Saklatvala J The p38 MAP kinase pathway as a therapeutic target in inflammatory disease Curr Opin Pharmacol 2004, 4:372-377. 15251131
5. Han J Lee JD Bibbs L Ulevitch RJ A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells Science 1994, 265:808-811. 7914033
6. Lee JC Laydon JT McDonnell PC Gallagher TF Kumar S Green D McNulty D Blumenthal MJ Heys JR Landvatter SW Strickler JE McLaughlin MM Siemens IR Fisher SM Livi GP White JR Adams JL Young PR A protein kinase involved in the regulation of inflammatory cytokine biosynthesis Nature 1994, 372:739-746. 7997261
7. Mielke K Herdegen T JNK and p38 stress kinases-degenerative effectors of signal-transduction-cascades in the nervous system Prog Neurobiol 2000 61 45 60 10759064
8. Schieven GL The biology of p38 kinase: A central role in inflammation Curr Topics Med Chem 2005, 5:921-928.
9. Roux PP Blenis J ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions Microbiol Mol Biol Rev 2004, 68:320-344. 419926 15187187
10. Guo X Gerl RE Schrader JW Defining the involvement of p38alpha MAPK in the production of anti- and proinflammatory cytokines using an SB 203580-resistant form of the kinase J Biol Chem 2003, 278:22237-22242. 12637577
11. Cuenda A Rousseau S p38 MAP-kinases pathway regulation, function and role in human diseases Biochim Biophys Acta 2007, 1773:1358-1375. 17481747
12. O'Keefe SJ Mudgett JS Cupo S Parsons JN Chartrain NA Fitzgerald C Chen SL Lowitz K Rasa C Visco D Luell S Carballo-Jane E Owens K Zaller DM Chemical genetics define the roles of p38α and p38β in acute and chronic inflammation J Biol Chem 2007, 282:34663-34671. 17855341
13. Shi Y Gaestel M In the cellular garden of forking paths: How p38 MAPKs signal for downstream assistance Biol Chem 2002, 383:1519-1536. 12452429
14. Zarubin T Han J Activation and signaling of the p38 MAP kinase pathway Cell Res 2005, 15:11-18. 15686620
15. Freshney NW Rawlinson L Guesdon F Jones E Cowley S Hsuan J Saklatvala J Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27 Cell 1994, 78:1039-1049. 7923354
16. Kotlyarov A Neininger A Schubert C Eckert R Birchmeier C Volk HD Gaestel M MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis Nat Cell Biol 1999, 1:94-97. 10559880
17. Culbert AA Skaper SD Howlett DR Evans NA Facci L Soden PE Seymour ZM Guillot F Gaestel M Richardson JC MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity J Biol Chem 2006, 281:23658-23667. 16774924
18. Winzen R Kracht M Ritter B Wilhelm A Chen CY Shyu AB Müller M Gaestel M Resch K Holtmann H The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism EMBO J 1999, 18:4969-4980. 1171568 10487749
19. Neininger A Kontoyiannis D Kotlyarov A Winzen R Eckert R Volk HD Holtmann H Kollias G Gaestel M MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels J Biol Chem 2002, 277:3065-3068. 11741878
20. Deak M Clifton AD Lucocq LM Alessi DR Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB EMBO J 1998, 17:4426-4441. 1170775 9687510
21. Saccani S Pantano S Natoli G p38-dependent marking of inflammatory genes for increased NF-kappa B recruitment Nat Immunol 2002, 3:69-75 11743587
22. Vermeulen L De Wilde G Van Damme P Berghe Vanden W Haegeman G Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1) EMBO J 2003, 22:1313-1324 151081 12628924
23. Olson CM Hedrick MN Izadi H Bates TC Olivera ER Anguita J p38 mitogen-activated protein kinase controls NF-kappaB transcriptional activation and tumor necrosis factor alpha production through RelA phosphorylation mediated by mitogen- and stress-activated protein kinase 1 in response to Borrelia burgdorferi antigens Infect Immun 2007, 75:270-277 1828394 17074860
24. Funding AT Johansen C Kragballe K Otkjaer K Jensen UB Madsen MW Fjording MS Finnemann J Skak-Nielsen T Paludan SR Iversen L Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines J Invest Dermatol 2006, 126:1784-1791 16543895
25. Jia Q Zhou HR Shi Y Pestka JJ Docosahexaenoic acid consumption inhibits deoxynivalenol-induced CREB/ATF1 activation and IL-6 gene transcription in mouse macrophages J Nutr 2006, 136:366-372 16424113
26. Raingeaud J Gupta S Rogers JS Dickens M Han J Ulevitch RJ Davis RJ Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine J Biol Chem 1995, 270:7420-7426 7535770
27. Andreakos E Targeting cytokines in autoimmunity: New approaches, new promise Expert Opin Biol Ther 2003, 3:435-447 12783612
28. Morel J Berenbaum F Signal transduction pathways: New targets for treating rheumatoid arthritis Joint Bone Spine 2004, 71:503-510 15589430
29. Bolos J Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors Mini Rev Med Chem 2005, 5:857-868 16178727
30. Kaminska B MAPK signaling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits Biochim Biophys Acta 2005, 1754:253-263 16198162
31. Miwatashi S Arikawa Y Kotani E Miyamoto M Naruo K Kimura H Tanaka T Asahi S Ohkawa S Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: Discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent J Med Chem 2005, 48:5966-5979 16162000
32. Mbalaviele G Anderson G Jones A De Ciechi P Settle S Mnich S Thiede M Abu-Amer Y Portanova J Monahan J Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction J Pharmacol Exp Ther 2006, 317:1044-1053 16501068
33. Medicherla S Ma JY Mangadu R Jiang Y Zhao JJ Almirez R Kerr I Stebbins EG O'Young G Kapoun AM Luedtke G Chakravarty S Dugar S Genant HK Protter AA A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis J Pharmacol Exp Ther 2006, 318:132-141 16597712
34. Dambach DM Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases Curr Top Med Chem 2005, 5:929-939 16178738
35. Goldstein DM Gabriel T Pathway to the clinic: Inhibition of p38 MAP kinase. A review of ten chemotypes selected for development Curr Top Med Chem 2005, 5:1017-1029 16178744
36. Dominguez C Powers DA Tamayo N p38 MAP kinase inhibitors: Many are made, but few are chosen Curr Opin Drug Discov Devel 2005, 8:421-430 16022178
37. Lee MR Dominguez C MAP kinase p38 inhibitors: Clinical results and an intimate look at their interactions with p38α protein Curr Med Chem 2005, 12:2979-2994 16378500
38. Peifer C Wagner G Laufer S New approaches to the treatment of inflammatory disorders with small molecule inhibitors of p38 MAP kinase Curr Top Med Chem 2006, 6:113-149 16454763
39. Stein B Yang MX Young DB Janknecht R Hunter T Murray BW Barbosa MS p38-2, a novel mitogen-activated protein kinase with distinct properties J Biol Chem 1997, 272:19509-19517 9235954
40. O'Dwyer ME Druker BJ The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer Curr Cancer Drug Targets 2001, 1:49-57 12188891
41. Munoz L Ralay Ranaivo H Roy SM Hu W Craft JM McNamara LK Chico LW Van Eldik LJ Watterson DM A novel p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model J Neuroinflammation 2007, 4:21 2014744 17784957
42. Wrobleski ST Doweyko AM Structural comparison of p38 inhibitor-protein complexes: A review of recent p38 inhibitors having unique binding interactions Curr Top Med Chem 2005, 5:1005-1016 16178743
43. Craft JM Watterson DM Marks A Van Eldik LJ Enhanced susceptibility of S100B transgenic mice to neuroinflammation and neuronal dysfunction induced by intracerebroventricular infusion of human β-amyloid Glia 2005, 51:209-216 15810011
44. Mrak RE Griffin WS Glia and their cytokines in progression of neurodegeneration Neurobiol Aging 2005, 26:349-354 15639313
45. Tuppo EE Arias HR The role of inflammation in Alzheimer's disease Int J Biochem Cell Biol 2005, 37:289-305 15474976
46. Hu W Ralay Ranaivo H Roy SM Behanna HA Wing LK Munoz L Guo L Van Eldik LJ Watterson DM Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits Bioorg Med Chem Lett 2007, 17:414-418 1868432 17079143
47. Bhat NR Zhang P Lee JC Hogan EL Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-α gene expression in endotoxin-stimulated primary glial cultures J Neurosci 1998, 18:1633-1641 9464988
48. Griffin WS Sheng JG Royston MC Gentleman SM McKenzie JE Graham DI Roberts GW Mrak RE Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression Brain Pathol 1998, 8:65-72 9458167
49. Li Y Liu L Barger SW Mrak RE Griffin WST Vitamin E suppression of microglial activation is neuroprotective J Neurosci Res 2001, 66:163-170 11592111
50. Jeohn GH Cooper CL Wilson B Chang RC Jang KJ Kim HC Liu B Hong JS p38 MAP kinase is involved in lipopolysaccharide-induced dopaminergic neuronal cell death in rat mesencephalic neuron-glia cultures Ann N Y Acad Sci 2002, 962:332-346 12076985
51. Kim SH Smith CJ Van Eldik LJ Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1β production Neurobiol Aging 2004, 25:431-439 15013563
52. Xie Z Smith CJ Van Eldik LJ Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38 Glia 2004, 45:170-179 14730710
53. Griffin WS Liu L Li Y Mrak RE Barger SW Interleukin-1 mediates Alzheimer and Lewy body pathologies J Neuroinflammation 2006, 3:5 1435743 16542445
54. Sheng JG Jones RA Zhou XQ McGinness JM Van Eldik LJ Mrak RE Griffin WS Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: Potential significance for tau protein phosphorylation Neurochem Int 2001, 39:341-348 11578769
55. Ferrer I Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice Neurotox Res 2004, 6:469-475 15658002
56. Reynolds CH Nebreda AR Gibb GM Utton MA Anderton BH Reactivating kinase/ p38 phosphorylates τ protein in vitro J Neurochem 1997, 69:191-198 9202310
57. Atzori C Ghetti B Piva R Srinivasan AN Zolo P Delisle MB Mirra SS Migheli A Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis J Neuropathol Exp Neurol 2001, 60:1190-1197 11764091
58. Ferrer I Blanco R Carmona M Puig B Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/ calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies J Neural Transm 2001, 108:1397-1415 11810404
59. Ferrer I Gomez-Isla T Puig B Freixes M Ribe E Dalfo E Avila J Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies Curr Alzheimer Res 2005, 2:3-18 15977985
60. Li Y Liu L Barger SW Griffin WS Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway J Neurosci 2003, 23:1605-1611 12629164
61. Giovannini MG Scali C Prosperi C Bellucci A Vannucchi MG Rosi S Pepeu G Casamenti F Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: Involvement of the p38 MAPK pathway Neurobiol Dis 2002, 11:257-274 12505419
62. Savage MJ Lin YG Ciallella JR Flood DG Scott RW Activation of c-Jun N terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition J Neurosci 2002, 22:3376-3385 11978814
63. Hensley K Floyd RA Zheng NY Nael R Robinson KA Nguyen X Pye ZN Stewart CA Geddes J Markesbery WR Patel E Johnson GV Bing G p38 kinase is activated in the Alzheimer's disease brain J Neurochem 1999, 72:2053-2058 10217284
64. Pei JJ Braak E Braak H Grundke-Iqbal I Iqbal K Winblad B Cowburn RF Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration J Alzheimers Dis 2001, 3:41-48 12214071
65. Sun A Liu M Nguyen XV Bing G p38 MAP kinase is activated at early stages in Alzheimer's disease brain Exp Neurol 2003, 183:394-405 14552880
66. Barone FC Irving EA Ray AM Lee JC Kassis S Kumar S Badger AM White RF McVey MJ Legos JJ Erhardt JA Nelson AH Ohlstein EH Hunter AJ Ward K Smith BR Adams JL Parsons AA SB 23 a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia J Pharm Exp Ther 9063, 296:312-321
67. Legos JJ Erhardt JA White RF Lenhard SC Chandra S Parsons AA Tuma RF Barone FC SB 23 a novel p38 inhibitor, attenuates early neuronal injury following ischemia Brain Res 9063, 892:70-77
68. Contreras JM Rival YM Chayer S Bourguignon JJ Wermuth CG Aminopyridazines as acetylcholinesterase inhibitors J Med Chem 1999, 42:730-741 10052979